| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | beclometasone/formoterol/glycopyrronium bromide (Riarify®) |
| Formulation | 87 micrograms/ 5 micrograms/ 9 micrograms inhalation solution |
| Reference number | 4164 |
| Indication | Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations) |
| Company | Chiesi Farmaceutici S.p.A. |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 04/04/2019 |